In the past 15 years there has been a growing trend for universities to spin-out biotech companies and to develop in-house drug discovery capabilities.
An academic group or early spin-off company will encounter many challenges in bringing a compound from the laboratory to clinical development. As is well-documented, drug discovery and development is a lengthy, complex, and costly process, entrenched with a high degree of uncertainty that a drug will actually succeed to reach patients. Indeed, it has been estimated that it now costs around $2.6 billion to develop a new drug, and on average it can take up to 12 years to enter the market.
In this document we explore the benefits of working with an experienced Contract Research Organization.
